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Abstract
Alternative splicing of the vascular endothelial growth factor A (VEGF-A) terminal exon generates two protein families
with differing functions. Pro-angiogenic VEGF-Axxxa isoforms are produced via selection of the proximal 3′ splice site of
the terminal exon. Use of an alternative distal splice site generates the anti-angiogenic VEGF-Axxxb proteins. A
bichromatic splicing-sensitive reporter was designed to mimic VEGF-A alternative splicing and was used as a molecular
tool to further investigate this alternative splicing event. Part of VEGF-A’s terminal exon and preceding intron were
inserted into a minigene construct followed by the coding sequences for two fluorescent proteins. A different
fluorescent protein is expressed depending on which 3′ splice site of the exon is used during splicing (dsRED denotes
VEGF-Axxxa and EGFP denotes VEGF-Axxxb). The fluorescent output can be used to follow splicing decisions in vitro and
in vivo. Following successful reporter validation in different cell lines and altering splicing using known modulators, a
screen was performed using the LOPAC library of small molecules. Alterations to reporter splicing were measured
using a fluorescent plate reader to detect dsRED and EGFP expression. Compounds of interest were further validated
using flow cytometry and assessed for effects on endogenous VEGF-A alternative splicing at the mRNA and protein
level. Ex vivo and in vitro angiogenesis assays were used to demonstrate the anti-angiogenic effect of the compounds.
Furthermore, anti-angiogenic activity was investigated in a Matrigel in vivo model. To conclude, we have identified a
set of compounds that have anti-angiogenic activity through modulation of VEGF-A terminal exon splicing.
Introduction
Alternative splicing (AS) is one of the main levels of
gene regulation in the eukaryotic cell; it affects >94% of
genes in humans1,2. Through AS, the diversity of proteins
in the cells (and therefore, protein functions) is greatly
increased. There are clear studies showing that splice
isoforms are not just a small modulation of the main
isoform function, but rather encode functions as diverse
as different genes3. Indeed, through AS the same gene is
even able to encode opposite functions in a cell; for
example, the apoptotic gene Bcl-2 has two protein iso-
forms including an anti-apoptotic isoform (Bcl-xL) and a
pro-apoptotic isoform (Bcl-xS), which is achieved by
switching an alternative 5′ splice site in exon 24.
A similar example is found in vascular endothelial
growth factor A (VEGF-A). Through usage of an alter-
native 3′ splice site, a novel family of isoforms (so called
“b” isoforms or VEGF-Axxxb) is produced that have the
same number of amino acids as the canonical isoforms,
but differ in the sequence of the last six amino acids – see
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Fig. 1A5. Binding to VEGF receptor 2 is affected; there-
fore, VEGF-Axxxb isoforms act as antagonist/partial ago-
nists. There has been a considerable amount of data from
laboratories across the world showing that the “b” iso-
forms have anti-angiogenic activity both in vitro and
in vivo6–10. The balance between the pro- and anti-
angiogenic isoforms has been shown to be regulated by
various signalling pathways: the canonical, proximal splice
site is under the control of the splice factor SRSF1 which
in turn is regulated by the splicing kinase SRPK1; the
distal splice site is defined by the splice factor SRSF6
whose action is modulated by the kinase Clk111. More
importantly, it has been shown that they have a functional
significance in disease, meaning that manipulation of
splice isoform levels is able to rescue phenotypes. For
example, the “b” isoforms are low in cancer and diabetic
nephropathy; however, overexpression or administration
of recombinant VEGF-A165b protein decreases tumour
growth in xenografts12 and decreases albuminuria in
diabetic nephropathy13. Normalisation of the VEGF-
Axxxa/ VEGF-Axxxb ratio is therefore an attractive ther-
apeutic target and makes finding small molecules that can
trigger the splicing switch a worthy endeavour.
A useful tool in screening for small molecule splicing
modulators is the so-called splicing-sensitive fluor-
escent reporter (SSFR), which is designed to give a
different fluorescence outcome depending on the spli-
cing pattern14–16.
We report here an unbiased, repositioning screen using
a bichromatic SSFR designed to mimic the splicing ratio
of VEGF-Axxxa to VEGF-Axxxb isoforms. We have found a
series of molecules, called ESSOs (named after the
researchers’ initials), that have been shown, upon valida-
tion, to have anti-angiogenic activity ex vivo and in vivo
and to decrease tumour growth in xenografts, through a
change in VEGF-A splicing.
Results
The design and validation of a splicing-sensitive
fluorescent reporter to mimic VEGF-A terminal exon
splicing
A bichromatic reporter template has been used based on
previously published designs14,17. This was engineered to
mimic VEGF-A exon 8 splicing. The reporter (termed pRG-
VEGF8ab) consists of the endogenous VEGF-A intron 7 and
required parts of exon 8, followed by the coding sequences
for two fluorescent proteins [see details in Methods section
and Stevens et al.15]. Depending on which 3′ splice site is
used for exon 8, a different fluorescent protein is expressed.
When the canonical, proximal splice site is used, dsRED is
formed followed by a stop codon, so EGFP is not produced.
When the distal splice site is used, there is a shift in the
reading frame (dsRED+ 1) and a fusion protein with EGFP
is produced (Fig. 1B). Therefore, dsRED denotes the pro-
angiogenic VEGF-Axxxa isoforms, and EGFP denotes the
anti-angiogenic VEGF-Axxxb isoforms.
While this reporter has been used and validated by our
lab in vivo in a transgenic mouse model15 for the purpose
of this study – to use it in a screen – we wanted to pursue
more validation in vitro. This is to ensure it reproduces
Fig. 1 VEGF-A splicing-sensitive fluorescent reporter design. A Endogenous VEGF-A splicing patterns; terminal exon 8 alternative 3′ splicing
results in the anti-angiogenic “b” isoforms. B Parts of VEGF-A gene (intron 7 and relevant regions of exon 8) have been inserted into the bichromatic
reporter in such a way that splicing at the proximal splice site (PSS) of exon 8 results in formation of dsRED and then a stop codon is encountered, so
EGFP is not formed. When the distal splice site (DSS) is used, there is a shift in the reading frame (dsRED+ 1) and a fusion with EGFP is formed.
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the endogenous VEGF-A splicing pattern, including
response to several compounds known to affect VEGF-A
terminal exon splicing through inhibition of SRPK118.
The endogenous VEGF-A is present exclusively as the
pro-angiogenic isoform in HEK293 cells19. Transient
transfection of pRG-VEGF8ab into HEK293 cells resul-
ted in both a dsRED and EGFP signal being produced
(Fig. 2A, upper panel). This is not surprising, as in a
transient setting there are many copies of the reporter
inside the cells and this can swamp the splicing
machinery and the regulation of a particular splice site20.
However, when stable transfected HEK293 cells are
obtained, the reporter displays only dsRED fluorescence
(Fig. 2A, lower panel), which is expected for the exclu-
sive proximal splice site usage in this cell line. RT-PCR
analysis confirmed this expected splicing pattern, with
only a band observed for dsRED (Fig. 2B), and FACS
analysis shows exclusively dsRED positive cells (Fig. 2C).
On the other hand, when pRG-VEGF8ab is transfected
into proliferating conditionally immortalised podocytes,
reported before to have high levels of VEGF-A165b
21,
EGFP can predominantly be seen (Fig. 2D, upper panel).
However, when transfected in Denys-Drash podocytes –
previously reported to express predominantly the pro-
angiogenic VEGF-A165a isoform
19 – only dsRED is
observed as expected.
To further validate that the reporter behaves as expec-
ted we have used a set of SRPK1 inhibitors. We have
previously shown18,19,22 that SRPK1 phosphorylates the
splice factor SRSF1 and consequently promotes the
proximal splice site in the VEGF-A terminal exon, defin-
ing the pro-angiogenic VEGF-Axxxa isoform. If SRPK1
function is abrogated either genetically by knocked-down
or using inhibitors (SRPIN340 or SPHINX), there is a
switch in splicing towards the distal splice site and pro-
motion of the anti-angiogenic VEGF-Axxxb isoform. We
would therefore expect that treatment of cells transfected
with the pRG-VEGF8ab reporter with SRPK1 inhibitors to
shift fluorescence of the reporter from dsRED towards
EGFP. Indeed, as seen in Fig. 2E, there is a progressive and
Fig. 2 Validation of the reporter in cell culture. A Transfection of the reporter in HEK293 cells – upper panel: transient transfections (24 h) show
both dsRED and EGFP signal due to multiple copies of the reporter; lower panel – stable transfected cells display only dsRED fluorescence
corresponding to the VEGF-A terminal exon proximal splice site usage in these cells. B RT-PCR for the reporter shows correct splicing in HEK293 cells.
C FACS analysis of HEK293 stably transfected with the reporter shows dsRED fluorescence only (parentFluor area is the trace for naïve untransfected
cells). D In proliferating conditionally immortalised human podocytes, selection of the reporter’s distal splice site leads to EGFP expression. No dsRED,
only EGFP expression was observed in transfected podocytes indicating an anti-angiogenic splicing pattern (upper panel). In Denys Drash Syndrome
(DDS) podocytes, where the VEGF-Axxxb isoforms are not expressed, we see only dsRED expression. Transfection efficiency is estimated at 20%.
E SRPK1 inhibition increases use of the pRG-VEGF8ab reporter distal splice site (dsRED/EGFP), as measured by the plate reader. n= 3, *P < 0.05. No
significant difference in dsRED+EGFP measurements. F The reporter was further validated after stable transfection into PC3 cells, Both SRPK1
inhibitors resulted in an increase in the EGFP/dsRED ratio. n= 3, *P < 0.05 vs DMSO. G To determine whether the reporter splicing mimics that of
endogenous VEGF-A, PC3 cells were treated with the same SRPK1 inhibitors. The protein VEGF-A165b/panVEGF-A165 ratio was increased after
treatment with SRPIN340 and SPHINX, although only significant with the more potent SRPK1 inhibitor, SPHINX. n= 3, *P < 0.05 vs DMSO.
Star et al. Oncogenesis           (2021) 10:36 Page 3 of 12
Oncogenesis
significant decrease in dsRED/EGFP ratio (indicating
splicing changes) when HEK293 cells stably transfected
with pRG-VEGF8ab are treated with inhibitors with
increasing potency (SPHINX7 more potent than SPHINX
which is more potent than SRPIN340). Remarkably, when
treated with a control inhibitor that mimics SPHINX7 but
it is chemically inert, there is no shift in the splicing ratio.
Additionally, there is no movement with any inhibitor in
the (dsRED+ EGFP) values on the X-axis, indicating that
these inhibitors do not affect the reporter expression.
We next stably transfected PC3 cells with pRG-
VEGF8ab to further validate the reporter at the mRNA
level using RT-PCR. In control treated PC3s, dsRED was
predominantly expressed at the mRNA level, which
equates to this cells line having a high expression of pro-
angiogenic VEGF-A isoforms18. Treatment of the trans-
fected PC3 cells with SPRIN340 and SPHINX (10 μM,
48 h) resulted in a significant increase in the EGFP/dsRED
ratio at the mRNA level (*P < 0.05; Fig. 2F). We next used
Western blotting to determine the protein expression of
the endogenous VEGF-A isoforms in PC3s exposed to the
same conditions. Both SRPIN340 and SPHINX increased
the VEGF-A165b/panVEGF-A165 ratio, although this was
only significant with the more potent SPHINX (*P < 0.05;
Fig. 2G).
Of note, even in an in vivo setting the reporter responds
accurately to SRPK1 inhibitors – when transgenic mice
harbouring the pRG-VEGF8ab reporter are treated
intraperitoneally with SPHINX injections, there is a
reporter switch in the expected direction ascertained by
both fluorescence and RT-PCR15.
Additionally, we have recently reported23 that a natural
blueberry extract (DIAVIT) upregulates production of
VEGF-A165b isoforms in podocytes. Indeed, when stably
transfected HEK293 cells were treated with DIAVIT, the
reporter dsRED/EGFP splicing ratio decreases as expec-
ted, in a dose-dependent manner (Supplementary Fig. 1).
The fact that the reporter responds in a similar way to
the endogenous VEGF-A terminal exon splicing gave us
confidence that it can be used to study the regulation of
this splicing event.
Screening for VEGF-A splicing modulators
In a quest to uncover novel anti-angiogenic compounds
that are able to modify VEGF-A splicing we set-up a
screen using the splicing reporter described. We have
chosen a repositioning screen using the LOPAC (library
of pharmacologically active compounds; Sigma, Inc). The
LOPAC library is formed of 1280 compounds that are
pharmacologically active, either marketed drugs or phar-
maceutically relevant structures. The library is designed to
cover most signalling pathways and major drug target
classes. Due to one of the goals of this project – to find
modulators of angiogenesis with one major target being
tumour angiogenesis – we chose the prostate cancer PC3
cell line for screening.
The screen was done in three steps (see Fig. 3). Fol-
lowing the primary screen, the first positive list of com-
pounds was screened for elimination of false positives that
may directly affect fluorescence or RNA stability. This was
done using cells stably transfected with control reporters
that lack the intron, cannot be spliced and mimic the
resulting dsRED or EGFP RNA of the two spliced iso-
forms (see step 2 in Fig. 3). Finally, due to the inherent
errors in any methodology, the resulting compound list
after the control screen were re-screened using a different
method – FACS. A hit-list of 9 compounds (called ESSOs)
resulted after this last step of screening – see Table 1.
ESSO compounds validation
To validate the main hit compounds described above,
RT-PCR and western blot analysis were performed on
PC3 cells individually treated with ESSO compounds at
10 μM for 48 h. At the mRNA level, ESSO 1, 3, 8 and 9
resulted in a significant switch in splicing towards the
VEGF-A165b isoforms (Fig. 4A). Furthermore, both
ESSO1 and 3 showed a significant increase in the VEGF-
A165b/panVEGF-A165 ratio at the protein level in PC3
cells, whereas ESSO 5 and 6 resulted in a significant
decrease in panVEGF-A165 expression Fig. 4B).
The effect of the compounds of the protein VEGF-
A165b/panVEGF-A165 ratio was also assessed in podo-
cytes, a cell line with a higher endogenous level of
VEGF-A165b
19,21 We found that treatment of podocytes
for 48 h with 10 μM ESSO1 and ESSO3 resulted in a
significant increase in the VEGF-A165b/panVEGF-A165
ratio at the protein level, as well as a significant decrease
in panVEGF-A165 expression (Fig. 4C).
ESSOs may not regulate VEGF-A splicing by direct
interaction with the spliceosome or the RNA
ESSOs are part of a repositioning library composed of
either substances that are approved drugs or chemicals
that were developed for drug purposing. While for most
of them, the mechanism of action and signalling pathways
involved are known (Fig. 5A), it is not clear whether or
not the new activity they are tested for (angiogenesis
inhibition) occurs through the same mechanism – e.g.
ESSO8 is an RTK (receptor tyrosine kinase) inhibitor –
does its activity on VEGF-A splicing and angiogenesis
depend on RTK signalling?
A number of small molecules are known to directly
target core components of the splicing machinery24. To
test the possibility that one or more of the ESSOs might
affect VEGF-A alternative splicing by directly targeting
components of the splicing machinery, we used cell-free
in vitro splicing assays. Radiolabelled pre-mRNA sub-
strates containing VEGF-A exon 8a and 8b 3′ splice sites
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and 365 nt of the adjacent upstream intron 7, with a
constitutive Tpm1 5′ exon and splice site were transcribed
in vitro and then incubated in HeLa cell nuclear extract.
The RNAs spliced exclusively using the VEGF-A 8a 3′
splice site in HeLa extract (Fig. 5B and Supplementary Fig
2A). When the predicted exon 8a branch sites were
weakened by A to G point mutations at −30 and −31 nt
upstream (Supplementary Fig 2A), the efficiency of 8a
splicing was substantially reduced, with no concomitant
upregulation of 8b splicing. This suggests that splicing of
exon 8b requires specific activation. We then tested the
effects of ESSO compounds at 1, 5 and 10 μM con-
centration. The ESSOs either had no effect or modestly
increased exon 8a splicing (Fig. 5B and Supp Fig. 2B).
However, none of the ESSO compounds detectably acti-
vated exon 8b splicing. These results therefore suggest
that the ESSO compounds do not directly target the
splicing machinery to affect VEGF-A 8a vs 8b splicing, but
more likely act upstream to regulate splicing indirectly.
The assay and our conclusions have limitations though, as
we do not have a positive control for exon 8b activation in
this assay.
ESSO compounds inhibit angiogenesis ex vivo
We further wanted to test whether the ESSO com-
pounds are able to inhibit angiogenesis. We first used
them in ex vivo Matrigel assays. There was a significant
decrease in the Matrigel tubule length with all ESSO
Fig. 3 Screening the LOPAC library for small molecules that effect the alternative splicing of the VEGF-A reporter construct. PC3 cells
transfected with the fluorescent VEGF splicing reporter were treated with the LOPAC compound library and reporter splicing measured using a
fluorescent plate reader (Primary screen, step 1). Hit compounds were used to treat non-splicing control reporter constructs (Control screen, step 2).
Flow cytometry was used to measure the effect of the hit compounds on reporter splicing (Secondary screen, step 3).
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compounds compared to DMSO control (Fig. 6A), sug-
gestive of anti-angiogenic properties. This was not due to
a toxic effect on the HUVECs as there was no difference
in cell viability with the various treatments, as assessed by
Trypan blue staining (Fig. 6B). To show that the effect is,
at least in part, due to a switch in VEGF-A splicing when
using ESSO1 and ESSO3, we performed a rescue experi-
ment in which antibodies specific to VEGF-A165b (56-1;
10 µg/ml) were also added while treating with ESSO1 and
3, as examples. As expected, this partially rescued the
effect of the ESSOs on Matrigel tubule length (Fig. 6C).
To further test ESSOs anti-angiogenic properties,
another assay was employed; an endothelial cell - fibro-
blast co-culture assay (Fig. 6D)25. Normal human dermal
fibroblasts (NHDF) were plated and after settling for 24 h,
HUVECs were added on top. Conditioned media from
PC3 cells treated with ESSOs (as above) was added to the
co-culture. Following incubation, cells were fixed and
stained with CD31 (an endothelial cell marker) and DAPI,
to visualise all cells in a particular well. While in control
conditions (DMSO), endothelial cells start proliferating
and migrating to form contacts (Fig. 6E, left upper panel),
this is inhibited in the presence of most ESSOs, of which
ESSO1 and ESSO7 were significant (see Fig. 6E, right
upper panel and quantification in the lower panel).
Furthermore, we found that addition to HUVEC cells of
conditioned media from PC3 cells treated with either
ESSO 1 or ESSO 3 resulted in a significant decrease in the
phosphorylation of VEGFR2 in comparison to a DMSO
control, further indicating that the increase in the VEGF-
A165b/VEGF-A165a ratio in response to ESSO treatment
has anti-angiogenic properties (Supplementary Fig. 3).
These results are consistent with our hypothesis that
ESSOs have anti-angiogenic activity ex vivo, some
through an effect on VEGF-A splicing.
ESSOs inhibit angiogenesis in vivo
To further investigate the effects of certain ESSOs on
angiogenesis, we employed an in vivo assay using Matrigel
plugs. We chose first to test ESSO 9 because out of the
four ESSOs that showed significant switch in VEGF-A
splicing, ESSO9 had the lowest efficiency (Fig. 4A). Cells
were incubated with either DMSO or ESSO9, mixed with
Matrigel and implanted subcutaneously in the back of
nude mice. Normally, small vessels from the mouse vas-
culature grow into the plug (see schematic Fig. 7A). In the
presence of anti-angiogenic activity, there is less vascu-
lature in the plug. Indeed, this is the case of ESSO9
treatment, as there was less red colour in the ESSO9-
treated plugs (Fig. 7B, C). Furthermore, we confirmed a
VEGF-A splicing switch to increase the VEGF-Axxxb iso-
form at the mRNA level in some of the plugs treated with
ESSO9 (Fig. 7D). Finally, we repeated this experiment
with ESSO1 and obtained similar results (Supplementary
Fig. 4). This shows that the two ESSOs, even if with dif-
ferent efficiencies in switching VEGF-A splicing, work
well in vivo to inhibit angiogenesis.
Discussion
Although discovered more than 50 years ago, with the
development of novel methods to analyse genomes
globally in the last 15–20 years, AS has appeared once
again in the scientific limelight because of its widespread
presence in human genes. AS has emerged as a central
mechanism in gene regulation that is able to modify the
functional repertoire of a cell through production of many
diverse proteins from a single gene. With the character-
isation of numerous AS isoforms came also the realisation
that many diseases express specific splice isoforms or that
normal ratios of isoforms are disrupted in disease. While a
certain percentage of these events may be just a silent by-
product of the pathological process progression, it is clear
that many of them have functional significance and
indeed, manipulation of their expression or splicing ratios
is beneficial to the disease phenotype. There is the pos-
sibility for splicing manipulation to work in a variety of
diseases, not only in diseases caused by splicing-related
mutations. This has therefore opened a new area where
novel therapeutics –modulators of AS –may be designed.
One strategy for modifying splicing outcomes is the use
of splicing-switching oligonucleotides (SSOs). These are
complementary short RNAs designed to anneal either at
splice sites or to mask various regulatory sequences.
While there are still hurdles to overcome until they
become good drugs in terms of systemic distribution,
bioavailability, etc, there are already successful examples
Table 1 Screened compounds shown to reduce the ratio
of dsRED/EGFP fluorescence intensity on the plate reader.
Compound Shortened name EGFP dsRED
Trovafloxacin mesylate ESSO01 ↑ ↓










Flupirtine maleate ESSO06 ↑ –
RepSox ESSO07 ↑ –
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like the FDA-approved SSOs to treat spinal muscular
atrophy or Duchenne muscular dystrophy26.
Another strategy is the use of small molecules to switch
splicing outcomes. Initially, this was not thought to be
feasible, as there were questions on how specific small
molecules can be for the hundreds of thousands of splice
sites that exist. In the splicing field this was argued to
be possible, as the three-dimensional conformation of the
RNA at splice sites combined with specific binding of splice
factors is able to give a unique conformation to which a
small molecule should be able to bind. However, this
remained under doubt until experimental data appeared –
to note two studies from Genentech and Roche using big-
size compounds library to find small molecules that can
switch SMN gene splicing in spinal muscular atrophy.
Indeed, compounds that intercalate between splice factors
and RNA have been found that are able to modulate the
splicing site targeted and be more specific than some of the
kinase inhibitors used today in the clinic27,28.
Small molecules that switch splicing may act either by
(i) interfering with signalling pathways (e.g., inhibiting a
splice-specific kinase that phosphorylates and activates a
specific splice factor); (ii) interfering with splice factor
binding at the splice sites and/or regulatory sequences;
(iii) disrupting protein–protein interaction needed at a
specific splice site; or by iv) altering the tertiary structure
of RNA at splice sites29. Indeed, one of these mechan-
isms has been described for modulation of VEGF-Axxxa
to VEGF-Axxxb ratio: inhibitors of the splicing kinase
SRPK111,19.
The aim of the present study was to identify novel
small molecules that are able to switch VEGF-A splicing
to increase the VEGF-Axxxb isoforms with an unbiased,
repositioning screen using a bichromatic SSFR. The
screen identified nine FDA-approved compounds,
ESSO1-9, which was narrowed down to four compounds
(ESSO 1, 3, 8 and 9) that had the most consistent effect
on splicing of the endogenous VEGF-A gene. These
compounds showed anti-angiogenic properties both
ex vivo and in vivo, which is indicated to be due to their
effect on VEGF-A splicing, demonstrating their ther-
apeutic potential in disease.
Fig. 4 Validation of ESSO compounds in vitro. A The effect of ESSO compounds on the alternative splicing of endogenous VEGF-A mRNA
transcripts. RNA was extracted from PC3 cells following 48 h treatment with ESSOs (10 μM), reverse transcribed and amplified by PCR. Anti-angiogenic
isoform transcripts were expected to be 66 bp smaller than pro-angiogenic transcripts. ESSO1, 3, 8 and 9 resulted in a significant shift in splicing to
increase VEGF-A165b at the mRNA level. n= 3, *P < 0.05 vs DMSO. B Changes in expression of anti-angiogenic VEGF-A protein isoforms upon
treatment of PC3s with ESSO compounds (example western blot). Following treatment with each small molecule (10 μM, 48 h), protein was extracted
and used for western blotting. The bands observed correspond to VEGF-A165b and VEGF-A165a/b isoform dimers (46 kDa). ESSO1 and 3 resulted in a
significant increase in VEGF-A165b relative to panVEGF-A165, whereas ESSO5 and 6 resulted in a significant decrease in both VEGF-A165 isoforms. n= 5,
*P < 0.05 vs DMSO. C Changes in expression of anti-angiogenic VEGF-A protein isoforms upon treatment of podocytes with ESSO 1 and 3
compounds (example western blot). Following treatment with each small molecule (10 μM, 48 h), protein was extracted and used for western
blotting. The bands observed correspond to VEGF-A165b and VEGF-A165a/b isoform dimers (46 kDa). ESSO1 and 3 resulted in a significant increase in
VEGF-A165b relative to panVEGF-A165, as well as a significant decrease in panVEGF-A165 expression. n= 8, *P < 0.05 vs DMSO.
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While understanding the complete mechanism through
which each ESSO compound acts to switch VEGF-A
splicing is beyond the scope of this manuscript, here are
some details of the ESSO compounds of most interest (see
also Table 1, Fig. 4A and Supplementary Fig. 5):
ESSO1 - trovafloxacin – is an antibiotic from the
fluoroquinolones class; it acts in bacteria by inhibiting
DNA gyrase and topoisomerase IV. It has been retracted
from the market due to potential hepatotoxicity;
microarray analysis of hepatocytes treated with trova-
floxacin has revealed widespread gene expression
modification including RNA processing genes30. Inter-
estingly, a screen using the same library as our study –
LOPAC – has identified trovafloxacin as a potent
inhibitor of pannexin channels. These channels have
been involved in a broad range of functions from
neutrophil activation to vasoconstriction and neurologi-
cal disorders31. We show here that trovafloxacin
significantly increased the endogenous VEGF-A165a/
VEGF-A165b ratio in PC3 and podocyte cells, resulting
in anti-angiogenic properties ex vivo.
ESSO2 – melatonin – is a hormone secreted by the pineal
gland, involved in regulation of the sleep-wake patterns.
While it has been previously known that melatonin has
anti-tumour and anti-angiogenesis effects, a recent study
has described a novel mechanism through which melato-
nin controls VEGF-Axxxa to VEGF-Axxxb splicing, and
consequently, the vasculature development in the sheep
pituitary gland32. Melatonin is therefore a positive control
for our screen. Although melatonin did not significantly
switch endogenous VEGF-A splicing in PC3 and podocyte
cells, it did display anti-angiogenic properties ex vivo.
ESSO3 – 5-[(4-Ethylphenyl)methylene]-2-thioxo-4-thiazoli-
dinone (10058-F4) – is a c-Myc inhibitor that specifically
inhibits c-Myc-Max heterodimerization and function, thus
preventing transactivation of c-Myc target gene expres-
sion. C-Myc is a transcription factor that has been
extensively studied due to its role as a proto-oncogene as
it plays an important role in the control of proliferation,
apoptosis and differentiation; its aberrant expression is
seen in multiple human cancers, including acute myeloid
leukaemia and pancreatic cancer. There are many reports
linking c-Myc to angiogenesis33,34. Furthermore, c-myc is
reported to regulate the transcription of several splice
factors including HNRNPA1, Sam68 and HNRNPH35–37.
Inhibition of c-Myc-Max using 10058-F4 (ESSO3) has
been previously reported to have a clinical benefit in some
cancers through effects on growth arrest, proliferation and
chemosensitivity38,39. However, the link to VEGF-A
splicing is a novel mechanistic connection related to
angiogenesis. We show that 10058-F4 significantly
increased the endogenous VEGF-A165a/VEGF-A165b ratio
in PC3 and podocyte cells, resulting in anti-angiogenic
properties ex vivo.
ESSO8 –GW2974 – is a potent and selective dual EGFR and
ErbB-2 receptor tyrosine kinase inhibitor. These receptors
Fig. 5 Mechanism of action of ESSOs. A Examples of known signalling mechanisms for ESSOs. B Splicing gels. Separation of products after 2 h
splicing reaction. Separated on 5% denaturing polyacrylamide gels. Positions of precursor, lariat intermediate, spliced product and lariat product
indicated. 5′ exon intermediate would be at 130 nt. Labelled DNA markers in left lane – sizes indicated to left.
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have been previously implicated in angiogenesis directly
or indirectly and their aberrant expression is considered
to be associated with tumour malignancy and poor
patient prognosis40. GW2974 has been reported to
inhibit tumour progression; in PC3 cells, GW2974 was
found to inhibit cell growth, indicating its potential in
the treatment of prostate cancer41. However, there are
no reports linking GW2974 to the regulation of AS. Our
data provides a new mechanistic link on how inhibition
of these receptor relates to splicing and angiogenesis as
GW2974 was found to significantly increase the
endogenous VEGF-A165a/VEGF-A165b ratio in PC3 cells,
as well as showing anti-angiogenic properties ex vivo.
ESSO9 - 4-(2-Aminoethyl) benzenesulfonyl fluoride
hydrochloride (AEBSF) – is an irreversible serine
protease inhibitor. Data on the effects of AESBF on
angiogenesis are very limited; however, one report has
linked AEBSF to the inhibition of angiogenesis through
inhibition of NADPH oxidase in vivo42. Our data may
provide further downstream links to VEGF-A in
modulating angiogenesis through the effects of AEBSF
on the VEGF-A165a/VEGF-A165b ratio in PC3 cells, in
addition to the anti-angiogenic properties of AEBSF both
ex vivo and in vivo.
When testing compounds in repositioning screens, the
mechanism for the novel effect could be completely dif-
ferent from the canonical one. We therefore tested whe-
ther some ESSO compounds may have a direct effect on
the splioceosome/RNA by using them in a nuclear extract
splicing asay (Fig. 5B). While the conclusions we can draw
from this assay are limited because we do not have a
positive control, we believe their effect to be through
canonical signalling pathways.
A limitation of this reporter system is that the dsRED/
EGFP ratio may not represent the exact splicing ratio of
the endogenous VEGF-A splice isoforms at the protein
level. Potential reason for this may be the stability of the
mRNA or post-transcriptional regulation mechanisms.
However, this does not negate the value of this dual
reporter system in detecting directional changes in VEGF-
A splicing.
In conclusion, we believe AS, similar to other levels of
gene regulation including transcription or miRs, is an area
where therapeutic ideas may be developed in a range of
diseases. As demonstrated with the example of VEGF-A
AS presented in this paper, it is possible to revert disease
phenotypes by modulation of AS and it is feasible to use
small molecules to do this.
Fig. 6 ESSOs have anti-angiogenic function ex vivo. A Using a Matrigel angiogenesis assay ESSOs 1-9 resulted in a statistically significant decrease
in HUVEC tubule length, thus angiogenesis, compared to DMSO control. n= 5, *P < 0.05. B HUVEC cell viability is not altered by treatment with ESSO
compounds compared to DMSO control. n= 3, P= ns. C Anti-angiogenic VEGF-A isoforms mediate ex vivo inhibition of endothelial tube formation.
The presence of anti-VEGF-A165b (56-1; 10 μg/ml) significantly reversed the effect of ESSO 1 and 3 on tubule length. Three images of each well were
captured and quantified. n= 3, *P < 0.05 vs. DMSO control. #P < 0.05 vs. ESSO control. D Schematic of the fibroblast (NHDF) and endothelial cell
(HUVEC) co-culture experiment to assess angiogenic potential in the presence of ESSO-treated PC3 conditioned media. E Endothelial cell tubule
formation was significantly reduced by ESSOs 1 and 7 during endothelial fibroblast co-culture. Ten microscopic fields of each co-culture were
quantified for the total length of endothelial tubules formed normalised to the total cell area. n= 3, **P < 0.01 vs DMSO.




HEK293, PC3, Podocyte, HUVEC and NHDF cells were
sub-cultured from existing cultures within the lab.
HEK293, PC3 and NHDF cells were cultured in DMEM
(D6429, Sigma - St Louis, Missouri, USA) supplemented
with 10% foetal bovine serum (10270, GIBCO –Waltham,
Massachusetts, USA) and 1% penicillin streptomycin
(GIBCO). Podocytes and Human umbilical vein endo-
thelial cells (HUVECs) were cultured in EBM-2 media
(Lonza – Basel, Switzerland)) supplemented with EGM-2
Bulletkit (Lonza). All cell lines were cultured at 37 °C and
in a humidified incubator with 5% CO2.
Reporter construction
Details about reporter design are given in Stevens
et al.15 where we used it to construct a transgenic mouse.
LOPAC primary screen
A library containing 1280 FDA-approved chemicals,
LOPAC, Library of Pharmaceutically Active Compounds
(LO4200, Sigma-Aldrich) was used. Chemicals in the
library were dissolved DMSO at a stock concentration of
10 mM. PC3 pRG8ab cells were trypsinised and diluted to
8 × 104 cell/ml using DMEM. In all, 100 μl of the cell
solution was seeded into each well of a black 96-well plate.
The cells in each 96-well plate were treated with DMSO
only and 16 different compounds from the LOPAC in
triplicate at 10 μM. Wells of the outside edges of 96-well
plates were not used for treatments or measured for
fluorescence. Plates were incubated for 48 h at 37 °C.
Changes in reporter alternative splicing caused by treat-
ment with LOPAC compounds were measured using a
VICTOR X multi-label plate reader (Perkin Elmer –
Waltham, Massachusetts, USA). Each plate was measured
using VICTOR plate reader three times. DMSO treated
wells were used as control measurements and statistically
compared to treated wells from the same 96-well plate
using a one-way ANOVA.
FACS, RT-PCR and western blotting
These were performed by standard methods/conditions –
for details please see Supplementary Information
Endothelial cell tube formation assay
This was performed as previously described;23 for
details please see Supplementary Information
Angiogenesis co-culture assay and CD31
Immunofluorescence
These were performed as previously described;19 for
details please see Supplementary Information
Fig. 7 ESSO9 inhibits angiogenesis in vivo. A ESSO9-treated PC3 cells (48 h) were mixed with Matrigel. The Matrigel and control cells were injected
subcutaneously into nude mice. Four days post-injection, the plugs were removed and RNA was extracted. B, C Photographs were taken of each plug
and colour intensity quantified using ImageJ software. There was a significant reduction in ESSO9 plug intensity. n= 6, P= 0.0002. D RT-PCR for
VEGF-A splice variants showed a switch in splicing to increase VEGF-Axxxb isoforms in some ESSO9-treated plugs compared to DMSO controls (n= 3).
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Trypan Blue cell viability assay
Cells were washed and trypsinised and described pre-
viously and diluted to an approximate concentration of
2 × 105 cells per ml. In all, 0.5 ml of cell suspension was
transferred to a screw cap tube and mixed thoroughly
with 100 μl of 0.4% Trypan Blue stain. Cells and the stain
were incubated for 5 mins at room temperature. A hae-
mocytometer was filled and used to count cells under a
microscope. Stained cells were non-viable and unstained
cells were viable.
Matrigel plug angiogenesis assay
PC3 cells were cultured in media containing 10 μM
ESSO or DMSO for 48 h. Cells were detached from
culture plates and diluted in DMEM to a concentration
of 2 × 107 per ml and placed on ice. Matrigel basement
membrane protein (734–1100, VWR) was thawed on
ice. In total, 100 μl of cell suspension was mixed with
400 μl of Matrigel and 10 μM of the test compound. The
mix of cells and matrix was subcutaneously injected into
each upper flank of Crl:CD1-Foxn1nu nude mice (males,
2 months old; Charles River). Four days post-injection,
mice were culled by cervical dislocation (Schedule 1)
and the Matrigel plugs were extracted. Images of each
plug were taken, and their colour quantified using
Photoshop as an indication of blood vessel infiltration
into the matrix. Plugs were flash frozen in liquid
nitrogen. In total, 1 ml of Trizol was added to each plug
and samples were homogenised for RNA extraction as
described.
In vitro splicing assays
were carried out in HeLa cell nuclear extract as
described previously43. Transcripts contained 365 or
165 nt of VEGF-A intron 7 immediately upstream of the
exon 8a 3′ splice site and 220 nt of exon 8, including the
8b 3′ splice site followed by a BamHI restriction site. The
5′ exon, 5′ splice site and first 150 nt of the intron were
from rat Tpm1 exon 1. Run-off transcripts were gener-
ated with T7 RNA polymerase from BamHI linearised
template in the presence of α-[32P]UTP. Spliced RNA
products were separated on 5 or 6% denaturing poly-
acrylamide gels and analysed by autoradiography or
phosphorimager for quantitation.
Statistical analysis
Comparisons of two datasets were performed using
Students’ t test or a Mann–Whitney U test, depending on
whether the data met the normal distribution. A com-
parison of three or more groups was performed using
one-way analysis of variance (ANOVA) with Dunnett’s
post-test. P < 0.05 was considered to indicate a statistically
significant difference.
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